Loading
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Latest quote
$2.44
−$0.01 · -0.41%
After-hours
$2.45
+$0.01 · +0.41%
Sep 16, 7:33 PM ET
Regular session · ET · Market data may be delayed.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Day range
Current $2.44
52-week range
Current $2.44
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
25
Expensive
Sentiment
59
Mixed
Risk
60
Elevated Risk
Momentum
29
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Day range
Current $2.44
52-week range
Current $2.44
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 21.82M USD | 18.8M USD | 8.44M USD | 1.34M USD | 8.5M USD |
| Selling, general, and administrative | 10.48M USD | 9.17M USD | 6.52M USD | 2.14M USD | 7.45M USD |
| Operating expenses | 28.29M USD | 18.23M USD | 7.81M USD | 3.48M USD | 24.68M USD |
| Interest income | 1.34M USD | 1.94M USD | 219.43K USD | 62.23K USD | 137.49K USD |
| Interest expense | — | — | — | 587 USD | — |
| Depreciation and amortization | — | — | — | — | 93.42K USD |
| Operating income | −28.29M USD | −18.23M USD | −7.81M USD | −3.48M USD | −24.68M USD |
| Net income | −26.97M USD | −16.29M USD | −2.17M USD | −5.8M USD | −24.1M USD |
Company facts updated Sep 17, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$7.00
186.89% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWC
Avantis U.S. Small Cap Equity ETFAVSCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
